Exparel for Pain Control During Care of Rib Fractures

Withdrawn before enrolling · Phase 4

Conditions studied: Pain

In brief

This study is looking at a novel therapy of numbing medication injected directly around the fracture site. The purpose of this study is to determine if the study medication, EXPAREL®, is a viable alternative to current therapies for rib fractures.

Key facts

Study ID

NCT02390440

Run by

Michael Moncure, MD

People needed

0

Starts

2015-04-01

Expected to finish

2017-01-01

Last updated by the study team

2017-01-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients 18 years of age or older
• patients with three or more rib fractures occurring either unilaterally or bilaterally
• patients who are awake enough to assess pain severity

You may not qualify if…

• patients whose pain in other anatomical areas limit rib fracture pain assessment
• patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioids, or ketorolac
• patients who abuse alcohol or other drug substances
• patients on chronic opioid therapy (taken an opioid 5 of the last 7 days)
• pregnant patients
• severe hepatic impairment
• persistent pain patients requiring 20mg oral morphine equivalent or greater in the 24 hour period prior to sustaining multiple rib fractures
• allergies to common agents used in Exparel (bupivacaine, liposome)
• inability to provide informed consent

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.